Clinical trials: Allogeneic Disease
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Graft vs Host Disease
CC-4047 (Pomalidomide) for Graft vs. Host Disease
This study will test the safety and effectiveness CC-4047 (pomalidomide) in patients with advanced, steroid refractory graft-versus-host disease.
- Trial name
- NCT00770757
- Testing
- CC-4047
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Refractory Myasthenia Gravis
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
This study is a single-center, prospective, nonrandom, single-arm trial.
- Trial name
- NCT07243366
- Testing
- CD19-CAR-NK Cells Injection
- Volunteers
- 15 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Severe Systemic Sclerosis
Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis
Systemic sclerosis (SSc) is a rare, severe and chronic systemic autoimmune disease (AD) characterized by vasculopathy, immune dysregulation and fibrosis leading to multi-organ dysfunction (primarily skin, lungs, heart…
- Trial name
- MSC-AT-SSc (NCT06722105)
- Testing
- 2 infusions of MSC, 1 infusion of MSC
- Volunteers
- 18 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and…
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event
- Trial name
- ACALLO (NCT04716075)
- Testing
- Acalabrutinib 2x100 MG Oral Capsule + alloSCT
- Where
- 6 sites in Poland
- Volunteers
- 29 people
- Sponsor
- Polish Lymphoma Research Group
Breast Cancer
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00971737
- Testing
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Leukemia, Chronic Myeloid Leukemia
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the…
- Conditions
- Acute Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02487069
- Testing
- HSCT from MSD, HSCT from MUD, HSCT from HRD
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
CMV Infection, EBV Infection
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
To evaluate the safety and tolerability of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV).
- Conditions
- CMV Infection, EBV Infection, Stem Cell Transplant
- Trial name
- NCT06075927
- Testing
- Virus specific T cells
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Secondary-progressive Multiple Sclerosis
Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients
This will be a phase I, open, multicenter, international study performed by 3 participating centres across two countries (Italy and Switzerland).
- Trial name
- NSC-SPMS (NCT03282760)
- Testing
- Human Neural Stem Cells
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 24 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Hemophagocytic Lymphohistiocytosis (HLH)
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation.
- Trial name
- HSCT-HLH (NCT07905066)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Peking University People's Hospital
Graft Vs Host Disease
A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
This is an academic open-label, phase II randomized study in patients with steroid resistant severe acute Graft versus host disease (GvHD) who have had allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05132166
- Testing
- Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib., Decidual Stromal Cells
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT
The purpose of this study is to determine whether a reduced intensity conditioning regimen followed by allogeneic stem cell transplantation from unrelated donors is a feasible and effective treatment for patients with multiple…
- Trial name
- NCT00599495
- Testing
- allogeneic HSCT
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD.
- Trial name
- NCT06649201
- Testing
- Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor.
- Conditions
- Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- PTBCy (NCT04943757)
- Testing
- Bendamustine Hydrochloride, Cyclophosphamid
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.
- Trial name
- NCT07167537
- Testing
- OL-CD19-GDT
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Beijing GoBroad Hospital
Graves' Disease
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and systemic complications, as well as thyroid eye…
- Trial name
- NCT07261345
- Testing
- allogenic anti-CD19/BCMA CAR-T
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai Zhongshan Hospital
Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
This study investigates the effectiveness and safety of Maraviroc (an oral medication given twice daily given in addition to the standard GVHD prophylaxis) in preventing Graft versus Host Disease (GVHD) in patients undergoing…
- Trial name
- NCT00948753
- Testing
- Maraviroc 150 MG, Maraviroc 300 mg, Maraviroc 300 mg Phase II
- Volunteers
- 38 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma.
- Conditions
- Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma
- Trial name
- EBV-TCL-01 (NCT02580539)
- Testing
- Group A, Group B
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dr. Jean-Sebastien Delisle, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.